Curated News
By: NewsRamp Editorial Staff
April 02, 2026
Cancer Immunotherapy Market to Skyrocket to $311 Billion by 2031
TLDR
- Investors can gain an advantage by targeting cancer immunotherapy firms like Calidi Biotherapeutics, as the market is projected to grow from $144.8 billion in 2025 to $311.4 billion by 2031.
- The cancer immunotherapy market is expanding through extensive research pipelines and supportive regulatory frameworks, with Mordor Intelligence forecasting growth to $311.4 billion by 2031.
- Cancer immunotherapy advancements promise better patient outcomes and improved quality of life, making tomorrow brighter for those affected by cancer worldwide.
- Cancer immunotherapy is rapidly evolving, with companies like Calidi Biotherapeutics leading research that could transform cancer treatment and save countless lives.
Impact - Why it Matters
This news matters because it signals a transformative shift in cancer treatment, with immunotherapy poised to become a cornerstone of oncology care. For patients, this growth translates to more accessible, potentially life-saving treatments that harness the body's own immune system, offering hope beyond traditional chemotherapy and radiation. For investors and the healthcare industry, the projected market expansion to over $300 billion represents massive financial opportunities and underscores the critical importance of continued research and development funding. The supportive regulatory environment in markets like the U.S. further accelerates innovation, potentially bringing new therapies to market faster. This evolution impacts everyone from researchers and pharmaceutical companies to healthcare providers and patients, fundamentally changing how cancer is treated and managed globally.
Summary
A new report by Mordor Intelligence reveals explosive growth projections for the cancer immunotherapy market, forecasting it will surge from $144.8 billion in 2025 to a staggering $311.4 billion by 2031. This rapid expansion is driven by an extensive research pipeline and supportive regulatory frameworks in key markets like the United States, positioning cancer immunotherapy to claim an increasingly dominant share of the global oncology field. The report analyzes future projections, growth drivers, and key trends shaping this dynamic sector, highlighting the significant financial and medical potential of these innovative treatments.
Among the firms spearheading this research is Calidi Biotherapeutics Inc. (NYSE American: CLDI), a key player in the biotechnology landscape. The news release was published by BioMedWire (BMW), a specialized communications platform focused on the latest developments in biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides a suite of services including access to a vast network of wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. This infrastructure allows BMW to effectively disseminate information to investors, influencers, consumers, and the general public, cutting through market noise to provide unparalleled recognition and brand awareness for its clients.
For those seeking more detailed insights, the full report and further information are accessible through the provided links. BioMedWire serves as a convergence point for breaking news, insightful content, and actionable information in the biotech sector, powered by the broader IBN network. This announcement underscores the critical role of specialized financial and medical news platforms in communicating complex market analyses and company developments to a wide audience.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cancer Immunotherapy Market to Skyrocket to $311 Billion by 2031
